Last $9.92 USD
Change Today -0.23 / -2.27%
Volume 195.4K
CEMP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Key Developments

Cempra Initiates Phase 3 Clinical Trial in Patients with Uncomplicated Gonorrhea Infection

Cempra, Inc. announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections. The trial is being conducted in Australia and the U.S. and will enroll approximately 300 patients in a randomized 2-arm study with a single oral dose of 1000 mg of solithromycin compared with the standard of care, 500 mg of ceftriaxone administered intramuscularly and 1000 mg of oral azithromycin.

Cempra, Inc. - Analyst/Investor Day

Cempra, Inc. - Analyst/Investor Day

Cempra, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Cempra, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $16.4 million, or $0.49 per basic and diluted share, compared to a net loss of $4.2 million, or $0.16 per basic and diluted share, for the same period in 2013. Revenues were $1,897,000 compared to $4,568,000 last year. Loss from operations was $15,906,000 compared to $3,841,000 last year. For the six months, the company reported net loss of $33.4 million, or $1.01 per basic and diluted share, compared to a net loss of $14.6 million, or $0.57 per basic and diluted share, for the comparable period in the six months ended June 30, 2013. Revenues were $4,980,000 compared to $4,568,000 last year. Loss from operations was $32,397,000 compared to $13,859,000 last year.

Cempra, Inc. to Report Q2, 2014 Results on Jul 29, 2014

Cempra, Inc. announced that they will report Q2, 2014 results After-Market on Jul 29, 2014

Cempra, Inc., Q2 2014 Earnings Call, Jul 29, 2014

Cempra, Inc., Q2 2014 Earnings Call, Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $9.92 USD -0.23

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies
 

Industry Analysis

CEMP

Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.1x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.